Due to the progressive nature of cardiac disease often observed in patients with dystroglycanopathies and our Pomt1 cKO mice, we set out to examine the importance of O-mannosylated DG in preventing myofiber injury and aberrant remodeling. This evidence concerns the gene POMT1 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.